[An article in Lancet set a SBU report rocking. When SBU authors question their own conclusions: Who is to be trusted?].
作者信息
Rosengren Annika
机构信息
Medicinkliniken, Sahlgrenska Universitetssjukhuset/Ostra, Göteborg.
出版信息
Lakartidningen. 2005;102(9):617-8.
PMID:15804033
Abstract
摘要
相似文献
1
[An article in Lancet set a SBU report rocking. When SBU authors question their own conclusions: Who is to be trusted?].
Lakartidningen. 2005;102(9):617-8.
2
[The double messages about atenolol must be an issue for the SBU board].
Lakartidningen. 2004 Dec 2;101(49):4038, 4041; discussion 4041-2, 4045.
3
[Errors about SBU statement and atenolol].
Lakartidningen. 2005;102(7):503.
4
[Criticism against the atenolol meta-analysis remains].
Lakartidningen. 2005;102(6):412, 414; discussion 414-5.
5
[Noticeable meta-analysis of atenolol does not cover all aspects].
Lakartidningen. 2005;102(1-2):61-3.
6
[Atenolol or metoprolol as beta-blocker in the treatment of hypertension].
Ned Tijdschr Geneeskd. 2005 Aug 6;149(32):1808-9.
7
Atenolol versus other beta-adrenergic blockers.
J Am Coll Cardiol. 2009 Jun 2;53(22):2101-2; author reply 2106-7. doi: 10.1016/j.jacc.2008.11.067.
8
Atenolol and cardiovascular risk: an issue close to the heart.
Lancet. 2006 Feb 25;367(9511):627-9. doi: 10.1016/S0140-6736(06)68238-X.
9
[Atenolol or metoprolol as beta-blocker in the treatment of hypertension].
Ned Tijdschr Geneeskd. 2005 Oct 29;149(44):2482; author reply 2482-3.
10
Atenolol is dead: long live beta-blockade.
J Am Coll Cardiol. 2009 Jun 2;53(22):2102; author reply 2106-7. doi: 10.1016/j.jacc.2008.12.076.
Zotero 插件